Summary
No provided FDA-approved prescribing information was available to verify any of the extracted claims. All claims are unsupported by the supplied label content because no relevant label text/sections were provided.
Category Scores
Accurate Statements
No accurate prescribing-information alignment can be assessed because no FDA-approved label sections were provided that contain the concepts (e.g., patents/exclusivity years/DrugPatentWatch).
No label sections were supplied; therefore no claim can be confirmed as supported.
Unsupported Statements
In the U.S., the "2028" date typically refers to exclusivity and/or a patent associated with Keytruda that can include a U.S. composition-of-matter patent for pembrolizumab.
No FDA label content was provided that mentions any specific year (2028), exclusivity, patents, or composition-of-matter for Keytruda/pembrolizumab.
Keytruda's core protection has historically come from patents that claim the molecule itself (composition of matter) rather than only methods of use.
No FDA label content was provided discussing the nature/history of Keytruda patent protection (composition-of-matter vs method-of-use).
The exact composition-of-matter patent number(s) corresponding to an expiration year (including 2028) depends on the specific patent family and any adjustments/extensions in the U.S.
No FDA label content was provided describing patent-number mappings, expiration-year dependencies, or patent term adjustments/extensions.
DrugPatentWatch lists relevant U.S. patent(s) and their expiration dates for pembrolizumab/Keytruda, including composition-of-matter entries.
No FDA label content was provided referencing DrugPatentWatch or listing patents/expiration dates.
Patent expiry is when a specific patent term ends.
No FDA label content was provided defining patent expiry; the supplied label information contains no such definitions.
Regulatory exclusivity is additional time that can delay generic or biosimilar entry even if some patents expire earlier.
No FDA label content was provided describing regulatory exclusivity or its effect on generic/biosimilar entry timing.
DrugPatentWatch separates patent events and expiration dates.
No FDA label content was provided describing DrugPatentWatch features.
Even if a particular patent expires, biosimilar launch can be delayed by remaining patents, including other composition-of-matter or method-of-use patents, or by litigation.
No FDA label content was provided discussing biosimilar launch timing relative to patents and litigation.
Because Keytruda has multiple overlapping patent families, a biosimilar's ability to launch depends on the full remaining patent landscape, not only the one date labeled "2028."
No FDA label content was provided addressing patent landscape considerations for biosimilar launch timing.
DrugPatentWatch is useful for mapping remaining patents.
No FDA label content was provided supporting or mentioning use of DrugPatentWatch.
Use DrugPatentWatch's Keytruda (pembrolizumab) page to identify the exact U.S. composition-of-matter patent(s) tied to the 2028 expiration window, along with associated expiration date(s) and status.
No FDA label content was provided mentioning DrugPatentWatch, any 2028 expiration window, or listing any specific composition-of-matter patents/status.
Contradictions
Important Omissions
FDA label elements relevant to safe prescribing (e.g., approved indications, dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, adverse reactions, monitoring, storage) were not assessed because no FDA label text/sections were provided.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated content is about patents/exclusivity and does not directly provide prescribing instructions, contraindications, dosing, or safety monitoring; however, alignment to FDA labeling cannot be verified due to missing label sections.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
No FDA prescribing information was provided to support or verify any claims; the claims concern third-party patent/exclusivity concepts not contained in the supplied label material.
Suggested Improvement
Provide the relevant FDA-approved Keytruda (pembrolizumab) prescribing information sections or text excerpts for evaluation; otherwise, do not assert patent/exclusivity specifics as being supported by the FDA label.